A detailed history of Steward Partners Investment Advisory, LLC transactions in Argenx Se stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 360 shares of ARGX stock, worth $203,122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
360
Previous 364 1.1%
Holding current value
$203,122
Previous $156,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $1,736 - $2,207
-4 Reduced 1.1%
360 $195,000
Q2 2024

Aug 08, 2024

SELL
$356.01 - $451.55 $4,984 - $6,321
-14 Reduced 3.7%
364 $156,000
Q1 2024

May 15, 2024

BUY
$356.95 - $413.29 $9,637 - $11,158
27 Added 7.69%
378 $148,000
Q4 2023

Feb 12, 2024

SELL
$338.91 - $506.01 $677 - $1,012
-2 Reduced 0.57%
351 $133,000
Q3 2023

Nov 13, 2023

SELL
$369.35 - $548.43 $13,296 - $19,743
-36 Reduced 9.25%
353 $173,000
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $21,248 - $24,932
59 Added 17.88%
389 $151,000
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $20,388 - $24,622
61 Added 22.68%
330 $122,000
Q4 2022

Feb 15, 2023

SELL
$342.17 - $402.31 $4,106 - $4,827
-12 Reduced 4.27%
269 $101,000
Q3 2022

Nov 10, 2022

SELL
$343.2 - $395.75 $5,834 - $6,727
-17 Reduced 5.7%
281 $99,000
Q2 2022

Aug 04, 2022

BUY
$269.58 - $378.88 $33,427 - $46,981
124 Added 71.26%
298 $113,000
Q1 2022

May 02, 2022

BUY
$254.45 - $351.06 $24,681 - $34,052
97 Added 125.97%
174 $55,000
Q4 2021

Feb 08, 2022

SELL
$272.01 - $353.03 $272 - $353
-1 Reduced 1.28%
77 $27,000
Q3 2021

Nov 12, 2021

BUY
$295.0 - $350.58 $23,010 - $27,345
78 New
78 $24,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Steward Partners Investment Advisory, LLC Portfolio

Follow Steward Partners Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.